Immunic (NASDAQ:IMUX) Receives “Buy” Rating from D. Boral Capital

Immunic (NASDAQ:IMUX)‘s stock had its “buy” rating reiterated by research analysts at D. Boral Capital in a research report issued on Wednesday,Benzinga reports. They presently have a $17.00 price objective on the stock.

IMUX has been the topic of several other research reports. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target on shares of Immunic in a report on Friday, February 21st. StockNews.com lowered shares of Immunic from a “hold” rating to a “sell” rating in a report on Saturday. One research analyst has rated the stock with a sell rating, six have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $12.67.

Immunic Trading Down 4.2 %

Shares of IMUX stock opened at $1.15 on Wednesday. The company has a market capitalization of $103.59 million, a P/E ratio of -0.93 and a beta of 1.87. The business’s 50 day moving average is $1.03 and its two-hundred day moving average is $1.25. Immunic has a twelve month low of $0.92 and a twelve month high of $2.11.

Institutional Trading of Immunic

A number of hedge funds and other institutional investors have recently modified their holdings of IMUX. Connor Clark & Lunn Investment Management Ltd. raised its stake in Immunic by 70.8% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock valued at $169,000 after buying an additional 42,383 shares in the last quarter. State Street Corp increased its holdings in shares of Immunic by 7.5% in the 3rd quarter. State Street Corp now owns 167,145 shares of the company’s stock worth $276,000 after acquiring an additional 11,642 shares during the period. Jane Street Group LLC increased its position in Immunic by 121.4% in the 3rd quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock valued at $116,000 after acquiring an additional 38,553 shares during the period. Virtu Financial LLC acquired a new stake in Immunic in the third quarter worth about $50,000. Finally, HB Wealth Management LLC acquired a new stake in shares of Immunic in the 4th quarter worth approximately $81,000. 51.82% of the stock is owned by hedge funds and other institutional investors.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.